To investigate the prevalence and evolution of mucosal IgA and circulating IgA and IgG SARS-CoV-2 antibody titers and their relation to symptom severity and the presence of PCR-detectable (other) coronaviruses.
ID
Source
Brief title
Condition
- Viral infectious disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The main study outcome will be the prevalence of mucosal IgA and circulating
IgA and IgG SARS-CoV-2 antibodies.
Secondary outcome
Secondary study outcomes will be the evolution of the titers of these mucosal
IgA and circulating IgA and IgG SARS-CoV-2 antibodies over time and the
relation of their presence to symptom severity. Furthermore, the potential
relation between the presence of mucosal IgA SARS-CoV-2 antibodies and the
presence of PCR-detectable coronaviruses other than SARS-CoV-2 in saliva will
be assessed.
Background summary
Because of the current SARS-CoV-2 pandemic, in absence of a vaccine, it is of
great importance to know to what extent herd immunity forms in order to decide
on *social distancing* policies. In a recent informal, voluntary immunity
screening among 130 healthcare professionals, 70% of the people with
circulating antibodies were found to have isolated SARS-CoV-2 IgA in their
blood. This might indicate the role of the mucosal immunity in the defence
against SARS-CoV-2.
Study objective
To investigate the prevalence and evolution of mucosal IgA and circulating IgA
and IgG SARS-CoV-2 antibody titers and their relation to symptom severity and
the presence of PCR-detectable (other) coronaviruses.
Study design
The study design is an observational study, namely a prospective cohort study.
Study burden and risks
Blood and saliva will be sampled at 3-month intervals for immunological testing
for a total study duration of 24 months. Only if circulating SARS-CoV-2 IgA
and/or IgG antibodies are found, participants will receive a questionnaire. The
risks and burden associated with these study visits are considered to be
minimal.
Albinusdreef 2
Leiden 2333 ZA
NL
Albinusdreef 2
Leiden 2333 ZA
NL
Listed location countries
Age
Inclusion criteria
healthcare professionals working or having worked (in a department) with
COVID-19 patients within the LUMC
Exclusion criteria
below 18 years old
Design
Recruitment
metc-ldd@lumc.nl
metc-ldd@lumc.nl
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL74102.058.20 |